BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LV232 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LV232\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06828887-841@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:LV232: Phase 2 readout est. (NCT06828887)
DESCRIPTION:LV232\, phase 2\, Major Depressive Disorder.\nStudy: Dose-Findi
 ng Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in
  the Treatment of MDD\nEstimated primary completion: 1 September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lv232#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06828887
URL:https://assetmemo.bio/drug/lv232#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
